The association between regular use of aspirin and the prevalence of prostate cancer
Results from the National Health Interview Survey

Wan-Ting Huang (MS)a,b, Steven R. Erickson (PharmD)c, Richard A. Hansen (PhD)d, Chung-Hsuen Wu (PhD)a,e,

Abstract
Prostate cancer is prevalent with significant morbidity in the United States. Aspirin previously has been found to be associated with reduced carcinogenesis of prostate cells. However, it remains unclear whether regularly taking aspirin could lower the risk of prostate cancer. Therefore, our aim was to examine the association between self-reported regular use of aspirin and the prevalence of prostate cancer in a national sample of the US adult population.

The National Health Interview Survey is an annual survey conducted by the National Center for Health Statistics to investigate health and healthcare use of the US population. The current study is a population-based cross-sectional study using the 2010 National Health Interview Survey data. Adult male respondents who self-reported regularly taking aspirin at least 3 times per week were grouped as regular users. The prostate cancer prevalence was measured by respondents’ self-report of prostate cancer. Multivariable logistic regression models were used to evaluate the association between these 2 factors by adjusting for covariates selected based on Andersen Behavioral Model of Health Services Use.

An estimated 23 million (23.7%) males in the United States reported that they took aspirin regularly. Of them, 5.0% had prostate cancer. Regular aspirin use was significantly associated with a lower self-reported prevalence of prostate cancer after adjusting for predisposing, enabling, and need factors (odds ratio 0.60, 95% confidence interval 0.38–0.94).

Regular aspirin use was found to be significantly associated with a lower self-reported prevalence of prostate cancer in the United States in 2010. Further clinical trials and longitudinal studies are needed to confirm the causality between regular aspirin use and prostate cancer.

Abbreviations: BMI = body mass index, BPH = benign prostatic hyperplasia, CDC = Centers for Disease Control and Prevention, COX-2 = cyclooxygenase-2, MPB = male pattern baldness, NCHS = National Center for Health Statistics, NHIS = National Health Interview Survey, NSAIDs = nonsteroidal anti-inflammatory drugs, PSA = prostate-specific antigen.

Keywords: Andersen behavioral model of health services use, aspirin, National Health Interview Survey, prostate cancer

1. Introduction
Prostate cancer is a global health concern which affects about 1.1 million males in the world.[1] In the United States, prostate cancer accounts for 26% of male cancer patients[2] and is the leading cause of cancer death among males.[3] The estimated medical costs for prostate cancer were $11.9 billion in the United States in 2011,[4] and the projected incidence will reach 228,000 patients in 2030.[5]

Previous studies found aspirin use was associated with a reduced risk of several cancers, including colorectal cancer,[6,7] breast cancer,[8,9] and lung cancer.[10,11] However, whether aspirin could have similar benefits in patients with prostate cancer remains unknown. Results from animal and cellular studies indicated that the underlying mechanism of prostate cancer is related to the overexpression of cyclooxygenase-2 (COX-2).[12–14] Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can inhibit the production of COX-2 and can potentially reduce prostate carcinogenesis.[13,16]

Several recent population studies evaluating the association between aspirin use and the risk of prostate cancer found aspirin users had a slightly lower risk of prostate cancer.[16–18] However, these studies did not comprehensively account for risk factors of prostate cancer such as dietary,[19] physical activity, family
history, or medication use such as the use of finasteride, which could potentially reduce the risk of prostate cancer. Therefore, the purpose of this study is to evaluate the association between self-reported regular use of aspirin and the prevalence of prostate cancer in a national sample of the US male adult population. Our hypothesis is that male respondents’ self-reported regular use of aspirin is associated with a lower prevalence of prostate cancer.

2. Methods

2.1. Data source

We used cross-sectional data from the 2010 National Health Interview Survey (NHIS) to conduct this study. The NHIS is a yearly health survey conducted by the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), and it is widely recognized as the most comprehensive and reliable health survey of the civilian, noninstitutionalized, household population in the United States. Since 1987, every 5 years, the NHIS has added a cancer control supplement to the yearly survey. The supplement consists of 7 sections (diet and nutrition, physical activity, tobacco, cancer screening, genetic testing, family history, and survivorship) of cancer-related health questionnaires which comprehensively obtain health information from respondents who had cancer. The NHIS uses a multistage complex sample design with stratification and clustering to obtain US national estimates. The 2010 NHIS included 89,976 individuals from 35,177 families and the household response rate was 79.5%.

2.2. Study population and study design

This is a population-based cross-sectional study using the Person file, Sample Adult file, and Cancer Control Supplement file of the 2010 NHIS. A total of 11,986 adult male respondents were included. After excluding respondents whose age was less than 20 years, the final sample comprised of 11,657 adult males. Figure 1 shows the details of the enrollment process.

2.3. Dependent variables

The dependent variable of this study was self-reported prostate cancer prevalence, which was measured by 2 consecutive questions in the Sample Adult file. The first question asked was, “Have you EVER been told by a doctor or other health professional that you had cancer or a malignancy of any kind?” For respondents who answered yes to this question, a follow-up question was asked: “What kind of cancer was it?” Respondents who reported having “prostate cancer” were defined as patients who self-reported having prostate cancer.

2.4. Key independent variable

The key independent variable was whether respondents self-reported regularly taking aspirin, which was measured by a single question administered in the Cancer Control Supplement. The question asked was “Do you now take any of the following medications regularly, that is, at least 3 times a week? Aspirin, Bayer, Bufferin, or Excedrin?” Respondents who answered yes to this question were defined as regular aspirin users. Respondents who answered no to this question were defined as nonregular aspirin users.

2.5. Covariates

We used Andersen Behavioral Model of Health Services Use to select potential confounders associated with regular aspirin use and the prevalence of prostate cancer. Selected covariates were grouped into predisposing, enabling, and need factors, which we conceptualized to be predictive of prostate cancer. A literature search was conducted to guide selection of variables that could influence prostate cancer occurrence and aspirin use. For example, NSAID or COX-2 inhibitor use, dietary consumption, smoking status, family history, alcohol consumption, and exercise have previously been reported to be associated with prostate cancer occurrence and were included as covariates in our analysis. These variables were further categorized as predisposing, enabling, and need factors.
Predisposing factors included age (20–50, 51–65, 66–79, and ≥80 years), race/ethnicity (non-Hispanic White, Hispanic, non-Hispanic Black, non-Hispanic Asian, and others), education (less than high school, high school, some college, higher than college), US citizen (yes/no), and cancer-related health beliefs (measured by the self-perceived risk of cancer compared with average men, coded as less likely, about as likely, and more likely).

Enabling factors included insurance (yes/no), family income (measured by the ratio to the poverty threshold: <1.0, 1.00–1.99, and ≥2.0), region of residence (Northeast, Midwest, South, and West), regular finasteride use defined as taking at least 3 times per week (yes/no), regular use of nonaspirin NSAIDs or COX-2 inhibitors defined as taking at least 3 times per week (yes/no), and antidiabetic drug use (yes/no).

Need factors included family history of prostate cancer (measured by 2 variables: father had prostate cancer [yes/no] and brother had prostate cancer [yes/no]), smoking status (current, former, and never), alcohol drinking status (current, former, and never), frequency of vigorous physical activity (never/unable, less than once per week, 2 times per week, and over 3 times per week), nutritional status (measured by the frequency of dietary consumption of red meat, cheese, milk, calcium, and vitamin D), and health status (excellent, very good, good, fair, and poor), numbers of prostate-specific antigen (PSA) tests performed during the past 5 years (never, <5 times, 5–9 times, and ≥10 times), body mass index (BMI) (measured as a continuous variable), and self-reported diabetes mellitus (yes/no).

2.6. Statistical analysis

For descriptive statistics, we used Student t test and Wald chi-square test to describe and compare continuous and categorical patient characteristics between regular aspirin users and non-regular aspirin users. For inferential statistics, simple logistic regression models were used to test the association between each covariate and the prevalence of prostate cancer. A multivariable logistic regression model was used to evaluate the association between regular aspirin use and the prevalence of prostate cancer adjusting for predisposing factors, enabling factors, and need factors. To enhance the robustness of the regression model, we further tested the interaction term between age and regular aspirin use to ensure the interaction term was not significant.

All estimates were weighted to be nationally representative and account for the multistage, complex sample design in the NHIS. The sampling strategy of NHIS is multistage with stratification to form several primary sample units (PSU). After obtaining data from respondents in each PSU, the information was weighted back to obtain the national estimates of the US population. The sample weights were calibrated to 2000 census-based totals for sex, age, and race/ethnicity of the US civilian noninstitutionalized population. We used the SAS survey procedures (surveymeans, surveyfreq, and surveym Logistic) and standard Taylor Series Linearization methods to compute standard errors (SEs) and 95% confidence intervals (CIs). Two-tailed tests with a 0.05 level of significance were used to determine statistical significance. The study was approved as exempt human subjects research by the Taipei Medical University Joint Institutional Review Board, which is an ethics review panel.

2.7. Sensitivity analysis

Based on Andersen Behavioral Model of Health Services Use, the predisposing, enabling, and need factors were assumed to be independent of prostate cancer. Following this assumption, we performed sensitivity analyses by entering covariates (first, predisposing factors; second, enabling factors; and finally, need factors) into the multivariable logistic regression model in a hierarchical pattern to evaluate the relative contribution of each variable.

3. Results

Table 1 shows the characteristics of the male population. The estimated US male adult population was 106.6 million in 2010. An estimated 2.5 million male respondents (2.3%) reported that they ever had prostate cancer. The estimated number of regular aspirin users was about 23.4 million (23.7%). Roughly, 60.3% of the male respondents were aged 20 to 49 years and 69.1% were non-Hispanic white. The largest proportion of people lived in the Southern region (35.4%). About 1.3% of male respondents regularly took finasteride, and 14.8% regularly took nonaspirin NSAIDs or COX-2 inhibitors. Of the total sample, 21.7% were current smokers. More than half (52.5%) of the male respondents were either never or were unable to exercise, and 34.4% engaged in regular exercise more than 3 times a week. Approximately 90% of the male respondents never took calcium and vitamin D supplements. Most male respondents (87%) reported being in more than good health status. More than 70% of the male respondents did not receive a PSA test in the previous 5 years. Regarding cancer health beliefs, an estimated 10.7 million US males (11.4%) considered themselves as more likely to get cancer.

Table 2 shows the characteristics and comparison of the US male population with and without prostate cancer. Older people were more likely to have prostate cancer. Male respondents who believed that they had a higher risk of getting cancer were more likely to have prostate cancer (less likely: 1.7% vs about as likely: 1.9% vs more likely: 5.8%; P < 0.01). Respondents whose brothers had prostate cancer were more likely to report having prostate cancer (20.3% vs 2.0%; P < 0.01). Male respondents who were unable or never engaged in vigorous physical activity were more likely to have prostate cancer compared with male respondents with regular physical activity (never/unable: 3.0% vs less than once week: 1.3%, vs 2 times per week: 1.2%, vs over than 3 times per week: 1.9%; P < 0.01). Male respondents who took calcium or vitamin D supplements every day were significantly more likely to have prostate cancer. Patients who self-reported better health status were significantly less likely to have prostate cancer. Male respondents who received a PSA test more often were more likely to have prostate cancer, especially those who received the test more than 10 times in the past 5 years.

Table 3 shows the results of the main and sensitivity analyses. Results in the first sensitivity analysis (model 1) showed that regular aspirin use was associated with a lower self-reported prevalence of prostate cancer when compared with nonregular aspirin use after adjusting for predisposing factors, but the result was not statistically significant (odds ratio [OR] 0.95, 95% confidence interval [CI] 0.69–1.31). Results in the second sensitivity analysis (model 2) showed that regular aspirin use was associated with a lower self-reported prevalence of prostate cancer.
Table 1
Characteristics of the US male population in 2010.

| Variables                                      | Est. N  | %     | (SE)  |
|------------------------------------------------|---------|-------|-------|
| **Dependent variable**                         |         |       |       |
| Prostate cancer                                |         |       |       |
| Yes                                            | 2,457,316 | 2.3   | 0.15  |
| No                                             | 104,026,095 | 97.7  | 0.15  |
| **Key independent variable**                   |         |       |       |
| Regular use of aspirin                         |         |       |       |
| Yes                                            | 23,380,505 | 23.7  | 0.52  |
| No                                             | 75,423,375 | 76.3  | 0.52  |
| **Predisposing factors**                       |         |       |       |
| Age                                            |         |       |       |
| 20–50                                          | 64,290,766 | 60.3  | 0.63  |
| 51–65                                          | 26,723,614 | 25.1  | 0.52  |
| 66–79                                          | 12,449,878 | 11.7  | 0.39  |
| ≥80                                            | 3,133,466   | 2.9   | 0.17  |
| Ethnicity                                      |         |       |       |
| Non-Hispanic White                             | 73,695,436 | 69.1  | 0.61  |
| Hispanic                                       | 15,768,381 | 14.8  | 0.41  |
| Non-Hispanic Black                             | 11,530,799 | 10.8  | 0.42  |
| Non-Hispanic Asian                             | 4,923,282   | 4.6   | 0.23  |
| Others                                         | 679,826     | 0.6   | 0.11  |
| Education                                      |         |       |       |
| Less than high school                          | 18,532,625 | 18.1  | 0.44  |
| High school                                    | 25,579,959 | 25.0  | 0.54  |
| Some college                                   | 19,670,160 | 19.2  | 0.47  |
| Higher than college                            | 38,676,303 | 37.7  | 0.63  |
| **US citizen**                                 |         |       |       |
| Yes                                            | 96,639,027 | 90.8  | 0.35  |
| No                                             | 9,822,302  | 9.2   | 0.35  |
| **Health belief**                              |         |       |       |
| Risk of cancer compared with average men       |         |       |       |
| Less likely                                    | 35,745,599 | 38.0  | 0.55  |
| About as likely                                | 47,611,198 | 50.6  | 0.62  |
| More likely                                    | 10,698,554 | 11.4  | 0.36  |
| **Enabling factors**                           |         |       |       |
| Insurance                                      |         |       |       |
| Yes                                            | 84,386,364 | 79.5  | 0.49  |
| No                                             | 21,797,692 | 20.5  | 0.49  |
| Ratio of family income to the poverty threshold|         |       |       |
| <1.0                                           | 11,225,039 | 11.4  | 0.38  |
| 1.00–1.99                                      | 16,576,165 | 16.8  | 0.47  |
| ≥2.0                                           | 70,579,824  | 71.7  | 0.64  |
| Region                                         |         |       |       |
| Northeast                                      | 19,102,909 | 17.9  | 0.62  |
| Midwest                                        | 24,350,557 | 22.8  | 0.64  |
| South                                          | 37,783,469 | 35.4  | 0.69  |
| West                                           | 25,360,789 | 23.8  | 0.64  |
| **Regular finasteride use (at least 3 times per wk)** | | | |
| Yes                                            | 1,249,113  | 1.3   | 0.12  |
| No                                             | 97,356,711  | 98.7  | 0.12  |
| **Regular NSAIDs or COX-2 inhibitors use (at least 3 times per wk)** | | | |
| Yes                                            | 14,632,299 | 14.8  | 0.41  |
| No                                             | 84,155,917 | 85.2  | 0.41  |
| **Take antidiabetic agents**                   |         |       |       |
| Yes                                            | 8,270,558  | 7.8   | 0.29  |
| No                                             | 98,242,078 | 92.2  | 0.29  |
| **Need factors**                               |         |       |       |
| Family history of prostate cancer              |         |       |       |
| Father had prostate cancer                     | 3,785,674  | 4.0   | 0.21  |
| No                                             | 89,748,797 | 96.0  | 0.21  |
| Brothers had prostate cancer                   |         |       |       |
| Yes                                            | 1,239,593  | 1.3   | 0.13  |
cancer when compared with nonregular aspirin use after adjusting for predisposing and enabling factors, but the result again was not statistically significant (OR 0.86, 95% CI 0.61–1.21). Results in the main analysis (model 3) showed that regular aspirin use was significantly associated with a lower self-reported prevalence of prostate cancer when compared with nonregular aspirin use after adjusting for predisposing, enabling, and need factors (OR 0.60, 95% CI 0.38–0.94).

Table 1 (Continued)

| Variables                                      | Est. N | %     | (SE)  |
|------------------------------------------------|--------|-------|-------|
| Smoking status                                 |        |       |       |
| Current                                        | 22,951,158 | 21.7 | 0.45 |
| Former                                         | 28,017,874 | 26.4 | 0.50 |
| Never                                          | 54,967,518 | 51.9 | 0.58 |
| Alcohol drinking status                        |        |       |       |
| Current                                        | 75,015,086 | 71.6 | 0.56 |
| Former                                         | 15,885,223 | 15.2 | 0.40 |
| Never                                          | 13,865,864 | 13.2 | 0.45 |
| Vigorous physical activity                     |        |       |       |
| Never/unable                                   | 52,084,881 | 52.5 | 0.68 |
| Less than once week                            | 3,609,224 | 3.6   | 0.25 |
| 2 times per week                               | 9,392,504 | 9.5   | 0.33 |
| Over than 3 times per week                     | 34,060,553 | 34.4 | 0.58 |
| Dietary nutrition (last month)                 |        |       |       |
| Red meat (frequency)                           |        |       |       |
| Never                                          | 5,179,201 | 5.2   | 0.25 |
| Per day                                        | 13,165,670 | 13.2 | 0.47 |
| Per week                                       | 56,855,674 | 57.2 | 0.65 |
| Per month                                      | 24,204,067 | 24.3 | 0.57 |
| Cheese (frequency)                             |        |       |       |
| Never                                          | 7,143,747 | 7.2   | 0.28 |
| Per day                                        | 21,703,295 | 21.8 | 0.52 |
| Per week                                       | 48,078,052 | 48.4 | 0.66 |
| Per month                                      | 22,493,411 | 22.6 | 0.51 |
| Milk (frequency)                               |        |       |       |
| Never                                          | 16,600,212 | 16.6 | 0.38 |
| Per week                                       | 31,264,370 | 31.3 | 0.56 |
| Per month                                      | 17,113,075 | 17.1 | 0.49 |
| Calcium supplements                             |        |       |       |
| Not use                                        | 89,528,026 | 89.7 | 0.38 |
| Less than once per day                         | 3,680,698 | 3.7   | 0.22 |
| Everyday                                       | 6,559,474 | 6.6   | 0.29 |
| Vitamin D supplements                           |        |       |       |
| Not use                                        | 89,765,189 | 90.0 | 0.35 |
| Less than once per day                         | 2,419,815 | 2.4   | 0.17 |
| Everyday                                       | 7,572,432 | 7.6   | 0.31 |
| Health status                                  |        |       |       |
| Excellent                                      | 30,761,564 | 28.9 | 0.52 |
| Very good                                      | 34,520,569 | 32.4 | 0.56 |
| Good                                           | 28,209,444 | 26.5 | 0.48 |
| Fair                                           | 9,788,372 | 9.2   | 0.30 |
| Poor                                           | 3,272,552 | 3.1   | 0.19 |
| Numbers of PSA test past 5 yrs                 |        |       |       |
| Never                                          | 72,267,473 | 73.3 | 0.55 |
| <5 times                                       | 15,105,224 | 15.3 | 0.43 |
| 5–9 times                                      | 9,760,063 | 9.9   | 0.37 |
| ≥10 times                                      | 1,507,143 | 1.5   | 0.14 |
| BMI <30 (kg/m²)                                | 27.9 |       |       |
| Diabetes                                       |        |       |       |
| Yes                                            | 10,764,831 | 10.1 | 0.32 |
| No                                             | 95,751,522 | 89.9 | 0.52 |

Results from the 2010 National Health Interview Survey.

Cox-2 = cyclooxygenase-2, NSAID = nonsteroidal anti-inflammatory drug, PSA = prostate-specific antigen, SE = standard error.

*Weighted estimates of percentage and standard error of row percentage.

BMI measured as a continuous variable. Source: National Center for Health Statistics, 2010 NHS Sample Adult and Sample Adult Cancer Supplements, and age of study population is equal or greater than 20 years.
Table 2
Characteristics of prostate cancer among the US male population in 2010, extrapolated from the sample adult cancer supplement to the National Health Interview Survey.

| Variables                          | Patients with prostate cancer | Patients without prostate cancer |
|------------------------------------|-------------------------------|---------------------------------|
|                                    | Est. N = 284; Est. N = 2,457,316 | Est. N = 11,357; Est. N = 104,026,095 |
| **Key independent variable**       |                               |                                 |
| Regular use of aspirin             |                               |                                 |
| Yes                                | 1,168,907 5.0 0.44            | 22,208,779 95.0 0.44            |
| No                                 | 1,077,030 1.4 0.15            | 74,255,605 98.6 0.15            |
| **Predisposing factors**           |                               |                                 |
| **Age**                            |                               |                                 |
| 20–50                              | 41,079 0.1 0.05               | 64,182,142 99.9 0.05            |
| 51–65                              | 640,078 2.4 0.35              | 26,053,162 97.6 0.35            |
| 66–79                              | 1,230,029 9.9 0.85            | 11,207,660 90.1 0.85            |
| ≥80                                | 546,130 17.5 2.17             | 2,583,131 82.5 2.17             |
| **Ethnicity**                      |                               |                                 |
| Non-Hispanic White                 | 2,032,729 2.8 0.21            | 71,578,791 97.2 0.21            |
| Hispanic                           | 97,354 0.6 0.20               | 15,671,027 94.4 0.20            |
| Non-Hispanic Black                | 269,238 2.3 0.31              | 11,233,983 97.7 0.31            |
| Non-Hispanic Asian                | 42,007 0.9 0.42               | 4,878,456 99.1 0.42             |
| Others                             | 15,988 2.4 1.77               | 663,838 97.6 1.77               |
| **Education**                      |                               |                                 |
| Less than high school              | 380,654 2.1 0.31              | 18,127,274 97.9 0.31            |
| High school                        | 597,812 2.3 0.31              | 24,976,494 97.7 0.31            |
| Some college                       | 380,071 1.9 0.27              | 19,264,112 98.1 0.27            |
| Higher than college                | 909,076 2.4 0.30              | 37,719,257 97.6 0.30            |
| **US citizen**                     |                               |                                 |
| Yes                                | 2,429,102 2.5 0.16            | 94,095,612 97.5 0.16            |
| No                                 | 28,214 0.3 0.16               | 9,794,088 99.7 0.16             |
| **Risk of cancer compared with average men** |       |                                 |
| Less likely                        | 612,518 1.7 0.26              | 35,097,326 98.3 0.26            |
| About as likely                    | 927,226 1.9 0.20              | 46,640,836 98.1 0.20            |
| More likely                        | 620,975 5.8 0.71              | 10,066,628 94.2 0.71            |
| **Enabling factors**               |                               |                                 |
| **Insurance**                      |                               |                                 |
| Yes                                | 2,436,434 2.9 0.18            | 81,875,919 97.1 0.18            |
| No                                 | 20,882 0.1 0.06               | 21,757,646 99.9 0.06            |
| **Ratio of family income to the poverty threshold** |       |                                 |
| <1.0                               | 104,060 0.9 0.24              | 11,095,909 99.1 0.24            |
| 1.00–1.99                          | 282,065 1.7 0.29              | 16,261,164 98.3 0.29            |
| ≥2.0                               | 1,840,687 2.6 0.20            | 68,721,236 97.4 0.20            |
| **Region**                         |                               |                                 |
| Northeast                          | 454,055 2.4 0.29              | 18,613,431 97.6 0.29            |
| Midwest                            | 641,644 2.6 0.32              | 23,689,537 97.4 0.32            |
| South                              | 876,080 2.3 0.25              | 36,874,420 97.7 0.25            |
| West                               | 485,557 1.9 0.30              | 24,848,707 98.1 0.30            |
| **Regular finasteride use (at least 3 times per wk)** |       |                                 |
| Yes                                | 7,786 0.6 0.44                | 1,241,327 99.4 0.44             |
| No                                 | 2,223,714 2.3 0.15            | 95,036,272 97.7 0.15            |
| **Regular NSAIDs or COX-2 inhibitors use (at least 3 times per wk)** |       |                                 |
| Yes                                | 384,623 2.6 0.43              | 14,245,199 97.4 0.43            |
| No                                 | 1,861,314 2.2 0.17            | 82,200,355 97.8 0.17            |
| **Take antidiabetic agents**       |                               |                                 |
| Yes                                | 447,929 5.4 0.81              | 7,822,629 94.6 0.81             |
| No                                 | 2,009,387 2.0 0.15            | 96,166,335 98.0 0.15            |
| **Need factors**                   |                               |                                 |
| **Family history of prostate cancer** |                           |                                 |
| Father had prostate cancer         | 176,433 4.7 1.04              | 3,601,037 95.3 1.04             |
| No                                 | 1,896,227 2.1 0.15            | 87,764,049 97.9 0.15            |
| Brothers had prostate cancer       | 251,445 20.3 3.76             | 988,148 79.7 3.76               |
| No                                 | 1,937,843 2.0 0.15            | 93,334,359 98.0 0.15            |
| **Smoking status**                 |                               |                                 |
| Current                            | 143,658 0.6 0.17              | 22,778,678 99.4 0.17            |
4. Discussion

To the best of our knowledge, this is the first study to evaluate the association between regular aspirin use and the prevalence of prostate cancer in a national sample of the US male population. This is also the first study to use Andersen Behavioral Model of Health Services Use to comprehensively select risk factors and assess their associations with the risk of prostate cancer. In our study, regular aspirin use was found to be significantly associated with lower risk of prostate cancer.

Table 2 (Continued)

| Variables                                | Patients with prostate cancer | Patients without prostate cancer |
|------------------------------------------|------------------------------|---------------------------------|
|                                          | n = 284; Est. N = 2,457,316  | n = 11,357; Est. N = 104,026,095 |
| Former                                   | 1,099,917                    | 26,912,600                      |
| Never                                    | 1,169,968                    | 53,742,188                      |
| Alcohol drinking status                  |                              |                                 |
| Current                                  | 1,513,135                    | 73,432,840                      |
| Former                                   | 580,374                      | 15,295,775                      |
| Never                                    | 296,912                      | 13,557,616                      |
| Vigorous physical activity               |                              |                                 |
| Never/Unable                             | 1,537,079                    | 50,466,745                      |
| Less than once week                      | 45,185                       | 3,555,575                       |
| Over than 3 times per week               | 657,057                      | 33,378,704                      |
| Dietary nutrition (last month)           |                              |                                 |
| Red meat (frequency)                     |                              |                                 |
| Never                                    | 102,781                      | 5,066,197                       |
| Per day                                  | 122,922                      | 13,009,812                      |
| Per week                                 | 1,449,596                    | 55,364,531                      |
| Per month                                | 569,485                      | 23,623,784                      |
| Cheese (frequency)                       |                              |                                 |
| Never                                    | 190,983                      | 6,940,945                       |
| Per day                                  | 416,688                      | 21,239,128                      |
| Per week                                 | 1,139,443                    | 46,926,778                      |
| Per month                                | 476,098                      | 21,983,938                      |
| Milk (frequency)                         |                              |                                 |
| Never                                    | 291,080                      | 16,287,538                      |
| Per day                                  | 881,041                      | 33,990,105                      |
| Per week                                 | 815,620                      | 30,443,107                      |
| Per month                                | 273,451                      | 16,801,538                      |
| Calcium supplements                      |                              |                                 |
| Not use                                  | 1,696,544                    | 87,752,178                      |
| Less than once per day                   | 114,558                      | 3,566,128                       |
| Everyday                                 | 461,630                      | 6,080,223                       |
| Vitamin D supplements                    |                              |                                 |
| Not use                                  | 1,582,408                    | 88,088,543                      |
| Less than once per day                   | 63,144                       | 2,366,671                       |
| Everyday                                 | 615,060                      | 6,954,885                       |
| Health status                            |                              |                                 |
| Excellent                                | 351,176                      | 30,396,774                      |
| Very good                                | 724,091                      | 33,796,478                      |
| Good                                     | 870,811                      | 27,276,112                      |
| Fair                                     | 428,237                      | 9,336,463                       |
| Poor                                     | 83,001                       | 3,175,045                       |
| Numbers of PSA test past 5 yrs           |                              |                                 |
| Never                                    | 138,582                      | 72,065,126                      |
| <5 times                                 | 470,123                      | 14,614,761                      |
| ≥10 times                                | 590,971                      | 8,809,651                       |
| BMI (mean)                               |                               |                                |
| (Mean = 7.51)                            | (Mean = 7.90)                |                                |
| Diabetes                                 |                               |                                |
| Yes                                      | 601,905                      | 10,159,209                      |
| No                                       | 1,855,411                    | 93,829,755                      |

COX: cyclooxygenase-2; NSAID = nonsteroidal anti-inflammatory drug, PSA = prostate-specific antigen, SE = standard error.

* Percentage of column.
† Weighted estimates of percentage and standard error of column percentage.
‡ An adjusted Wald chi-square test for table larger than 2 x 2.
§ BMI measured as a continuous variable. Source: National Center for Health Statistics, 2010 NHIS Sample Adult and Sample Adult Cancer Supplements, and age of study population is equal or greater than 20 years.
### Table 3

Association between regular use of aspirin and prostate cancer prevalence: results from main and sensitivity analysis by adding predisposing, enabling, and need factors in a hierarchical pattern.

| Variables                                      | Model 1 (sensitivity analysis) | Model 2 (sensitivity analysis) | Model 3 (main analysis) |
|------------------------------------------------|-------------------------------|-------------------------------|-------------------------|
| Adjusted OR | 95% CI | p<sup>§</sup>       | Adjusted OR | 95% CI | p<sup>§</sup>       | Adjusted OR | 95% CI | p<sup>§</sup> |
| Key independent variable                        |                               |                               |                         |
| Regular use of aspirin                          | 0.75                          | 0.39                          | <0.01                   |
| Yes                                             | 0.95 (0.69–1.31)              | 0.86 (0.61–1.21)              | 0.60 (0.38–0.94)        |
| No                                              | Reference Reference           | Reference Reference           | Reference Reference     |
| Predisposing factors                            |                               |                               |                         |
| Age                                             | <0.01                         | <0.01                         | <0.01                   |
| 20–50                                           | 0.03 (0.01–0.17)              | 0.04 (0.01–0.20)              | 0.15 (0.02–1.05)        |
| 51–65                                           | Reference Reference           | Reference Reference           | Reference Reference     |
| 66–79                                           | 0.02 (5.64–8.32)              | 2.02 (3.24–7.79)              | 3.05 (1.81–5.14)        |
| ≥80                                             | 9.65 (5.87–15.89)             | 9.34 (5.47–15.93)             | 5.56 (2.79–11.07)       |
| Ethnicity                                       |                               |                               |                         |
| Non-Hispanic White                              | 0.02                          | 0.17                          | 0.36                    |
| Hispanic                                        | 0.66 (0.30–1.47)              | 0.74 (0.32–1.70)              | 0.93 (0.39–2.22)        |
| Non-Hispanic Black                              | 1.59 (1.07–2.35)              | 1.58 (1.07–2.48)              | 1.40 (0.78–2.52)        |
| Non-Hispanic Asian                              | 0.56 (0.18–1.75)              | 0.66 (0.20–2.20)              | 0.63 (0.15–4.52)        |
| Others                                          | 4.27 (0.80–22.74)             | 2.73 (0.36–24.66)             | 6.00 (0.75–48.08)       |
| Education                                       |                               |                               |                         |
| Less than high school                           |                               |                               |                         |
| High school                                     | 1.47 (0.90–2.39)              | 1.19 (0.71–1.98)              | 0.95 (0.49–1.83)        |
| Some college                                    | 1.86 (1.07–3.23)              | 1.35 (0.73–2.49)              | 0.87 (0.38–2.04)        |
| Higher than college                             | 2.04 (1.24–3.36)              | 1.57 (0.93–2.64)              | 0.83 (0.39–1.74)        |
| US citizen                                      |                               |                               |                         |
| Yes                                             | 1.81 (0.50–6.55)              | 1.34 (0.37–4.95)              | 1.68 (0.29–9.60)        |
| No                                              | Reference Reference           | Reference Reference           | Reference Reference     |
| Health belief                                    |                               |                               |                         |
| Risk of cancer compared with average men        |                               |                               |                         |
| Less likely                                     |                               |                               |                         |
| About as likely                                 | 1.37 (0.90–2.06)              | 1.21 (0.79–1.87)              | 1.14 (0.66–1.98)        |
| More likely                                     | 4.42 (2.84–6.89)              | 3.99 (2.48–6.42)              | 3.68 (2.03–6.68)        |
| Enabling factors                                |                               |                               |                         |
| Insurance                                       |                               |                               |                         |
| Yes                                             | 3.79 (1.02–14.04)             | 2.18 (0.61–7.88)              |                         |
| No                                              | Reference Reference           | Reference Reference           | Reference Reference     |
| Ratio of family income to the poverty threshold |                               |                               |                         |
| <1.0                                            |                               |                               |                         |
| 1.00–1.99                                       | 1.57 (0.70–3.55)              | 1.03 (0.39–2.76)              |                         |
| ≥2.0                                            | 2.02 (1.00–4.11)              | 1.00 (0.41–2.45)              |                         |
| Region                                          |                               |                               |                         |
| Northeast                                       |                               |                               |                         |
| Midwest                                         | 1.28 (0.62–2.01)              | 1.11 (0.61–2.02)              |                         |
| South                                           | 1.06 (0.67–1.70)              | 1.04 (0.61–1.78)              |                         |
| West                                            | 1.03 (0.60–1.79)              | 1.00 (0.52–1.93)              |                         |
| Regular finasteride use                         |                               |                               |                         |
| (at least 3 times per wk)                       |                               |                               |                         |
| Yes                                             | 0.13 (0.03–0.54)              | 0.07 (0.01–0.30)              |                         |
| No                                              | Reference Reference           | Reference Reference           | Reference Reference     |
| Regular NSAIDs or COX-2 inhibitors use          |                               |                               |                         |
| (at least 3 times per wk)                       |                               |                               |                         |
| Yes                                             | 1.13 (0.73–1.76)              | 1.31 (0.76–2.24)              |                         |
| No                                              | Reference Reference           | Reference Reference           | Reference Reference     |
| Take antidiabetic agents                        |                               |                               |                         |
| Yes                                             | 1.40 (0.90–2.19)              | 0.93 (0.43–1.99)              |                         |
| No                                              | Reference Reference           | Reference Reference           |                         |
| Need factors                                    |                               |                               |                         |
| Family history of prostate cancer               |                               |                               |                         |
| Father had prostate cancer                      |                               |                               |                         |
| Yes                                             | 1.16 (0.53–2.56)              |                         |                         |
| No                                              | Reference Reference           |                         |                         |
| Brothers had prostate cancer                    |                               |                               |                         |
| Yes                                             | 4.27 (2.04–8.93)              |                         |                         |

Huang et al. Medicine (2016) 95:25
with a lower prevalence of prostate cancer when compared
with nonregular aspirin use among the US male population
in 2010.

Previous studies have reported a similar finding that aspirin is
associated with a reduced risk of prostate cancer.\textsuperscript{[16,18]} In
contrast to past studies, 1 advantage of our study is that it

\begin{table}
\centering
\caption{Table 3 (Continued)}
\begin{tabular}{llllll}
\hline
Variables & Model 1\textsuperscript{*} (sensitivity analysis) & & & &
| & Model 2\textsuperscript{\ddagger} (sensitivity analysis) & & & &
| & Model 3\textsuperscript{\dagger} (main analysis) & & & \\
& Adjusted OR & 95\% CI & $p$ & Adjusted OR & 95\% CI & $p$ & Adjusted OR & 95\% CI & $p$ \\
\hline
No Smoking status & Reference & Reference & & & & & & & \\
Current & 0.44 & (0.18–1.12) & 0.22 & & & & & & \\
Former & 0.52 & (0.31–0.96) & 0.05 & & & & & & \\
Never & Reference & Reference & & & & & & & \\
Alcohol drinking status & & & & & & & & & \\
Current & 0.70 & (0.37–1.33) & 0.51 & & & & & & \\
Former & 0.66 & (0.30–1.44) & 0.30 & & & & & & \\
Never & Reference & Reference & & & & & & & \\
Vigorous physical activity & & & & & & & & & \\
Never/unable & Reference & Reference & 0.53 & & & & & & \\
Less than once week & 0.64 & (0.13–3.10) & 0.56 & & & & & & \\
2 times per week & 0.89 & (0.20–3.90) & 0.72 & & & & & & \\
Over than 3 times per week & 1.33 & (0.83–2.12) & 0.22 & & & & & & \\
Dietary nutrition (last month) & & & & & & & & & \\
Red meat (frequency) & & & & & & & & & \\
Never & Reference & Reference & 0.50 & & & & & & \\
Per day & 0.96 & (0.24–3.79) & 0.93 & & & & & & \\
Per week & 1.40 & (0.47–4.73) & 0.60 & & & & & & \\
Per month & 1.99 & (0.64–6.23) & 0.20 & & & & & & \\
Cheese (frequency) & & & & & & & & & \\
Never & Reference & Reference & 0.50 & & & & & & \\
Per day & 1.18 & (0.52–2.68) & 0.72 & & & & & & \\
Per week & 1.03 & (0.49–2.17) & 0.96 & & & & & & \\
Per month & 0.71 & (0.32–1.60) & 0.57 & & & & & & \\
Milk (frequency) & & & & & & & & & \\
Never & Reference & Reference & 0.50 & & & & & & \\
Per day & 1.36 & (0.74–2.50) & 0.20 & & & & & & \\
Per week & 1.71 & (0.88–3.33) & 0.20 & & & & & & \\
Per month & 0.69 & (0.31–1.53) & 0.57 & & & & & & \\
Calcium supplements & & & & & & & & & \\
Not use & Reference & Reference & 0.20 & & & & & & \\
Everyday & 1.41 & (0.66–3.04) & 0.57 & & & & & & \\
Vitamin D supplements & & & & & & & & & \\
Not use & Reference & Reference & 0.20 & & & & & & \\
Excellent & Reference & Reference & 0.18 & & & & & & \\
Very good & 1.19 & (0.57–2.47) & 0.72 & & & & & & \\
Good & 1.96 & (0.95–4.07) & 0.45 & & & & & & \\
Fair & 1.34 & (0.51–3.57) & 0.57 & & & & & & \\
Poor & 1.44 & (0.44–4.77) & 0.57 & & & & & & \\
Numbers of PSA test past 5 yrs & & & & & & & & & \\
Never & Reference & Reference & <0.01 & & & & & & \\
<5 times & 8.14 & (2.93–22.63) & 0.20 & & & & & & \\
5–9 times & 20.66 & (7.15–59.73) & 0.20 & & & & & & \\
≥10 times & 143.48 & (49.16–418.79) & 0.20 & & & & & & \\
BMI\textsuperscript{\ddagger} & 0.99 & (0.95–1.03) & 0.72 & & & & & & \\
Diabetes & Yes & 1.31 & (0.65–2.62) & 0.45 & & & & & & \\
No & Reference & Reference & & & & & & & \\
\hline
\end{tabular}
\end{table}

\textsuperscript{1}COX-2 = cyclooxygenase-2, NSAID = nonsteroidal anti-inflammatory drug, PSA = prostate-specific antigen, SE = standard error.

\textsuperscript{2}Adjusted OR: Adjusted for predisposing factors, enabling factors, need factors.

\textsuperscript{3}Adjusted OR: Adjusted for predisposing factors; model 2: adjusted for predisposing and enabling factors; model 3: adjusted for predisposing factors, enabling factors, need factors.

\textsuperscript{4}An adjusted Wald chi-square test for table larger than 2 \times 2.

\textsuperscript{5}BMI measured as a continuous variable.
comprehensively included several covariates to fully adjust the effect of regular aspirin use on the risk of prostate cancer. These covariates included are as follows: (1) nutritional variables, such as red meat, milk, cheese, calcium, and vitamin D supplements; (2) lifestyle factors, such as exercise, smoking habits, and alcohol consumption; and (3) health belief of cancer risk. These covariates, which were not fully adjusted in past studies, were assumed to be risk factors to be associated with prostate cancer. Furthermore, our study is a theory-based study in which Andersen Behavioral Model of Health Services Use was used as a theoretical framework to guide the process of covariate selection.

In our study, we did not find a significant association between NSAID use and the reduced prevalence of prostate cancer. Whether the use of NSAIDs could reduce the risk of prostate cancer remains unclear, and findings from previous studies were controversial.[16-18] For example, Jacobs et al.[17] used the American Cancer Society’s Cancer prevention Study II Nutrition cohort to evaluate the impact of aspirin and NSAID use on prostate cancer incidence. They found that regular use of NSAIDs in the past 5 or more years was associated with a reduced risk of prostate cancer, but current NSAID use was not associated with decreased prostate cancer risk.[17] The measurement of NSAID use in our study was based on self-report reflecting whether respondents reported current use of nonaspirin NSAIDs or COX-2 inhibitors. Similar to the Jacobs et al.’s study,[17] we did not find a significant association between NSAID use and a reduced risk of prostate cancer. This might be attributed to the specificity of the survey questions. The question was originally phrased as “Do you now take any of the following medications regularly, that is, at least 3 times a week . . . Advil, Ibuprofen, Motrin, Naprin, Aleve, Naprosyn, Naproxen, or Celebrex?” The question mixed traditional NSAIDs and more selective NSAIDs such as Celebrex together and it was not possible to distinguish the effect of each NSAID on the risk of prostate cancer. Therefore, NSAIDs, unlike aspirin, could have differing mechanisms, which may or may not be associated with a lower prevalence of prostate cancer. Therefore, further research is necessary to determine whether the use of NSAIDs is associated with reduction in the prevalence of prostate cancer.

Several covariates such as patients’ health belief, family history, age, smoking status, regular finasteride use, and the number of PSA tests in the past 5 years were also found to be associated with a lower prevalence of prostate cancer. For example, respondents with a belief that they were more likely to get cancer had a higher self-reported prevalence of prostate cancer. Patients with a strong cancer health belief could be more likely to have a prostate screen, which can result in a higher likelihood of being diagnosed with prostate cancer.[63] Regarding family history, we found respondents whose brothers had prostate cancer were associated with a higher self-reported prevalence of prostate cancer. Similar to previous studies, family history is a risk factor for prostate cancer.[20,40,48]

Moreover, we found respondents who had a higher number of PSA tests in the past 5 years had an increased prevalence of prostate cancer. Because PSA testing has increased in the past decade,[21,51] the incidence of prostate cancer is rising proportionately through earlier diagnosis. This might be countered by the argument that there is high detection bias with the PSA test.[21,54,55] but respondents who received PSA testing more frequently still had a higher likelihood of being diagnosed with prostate cancer.

Diet has been considered as a possible risk factor for prostate cancer.[19,36,51] In our study, we did not find dietary factors to be associated with an increased prevalence of prostate cancer. The discrepancy between our findings and previous findings could be a function of the measurement of the dietary covariates, and therefore such a relationship cannot be ruled out completely.

Finally, we found finasteride use was associated with a lower prevalence of prostate cancer. In a 7-year trial, finastate, a 5 alpha-reductase inhibitor that was used to treat benign prostatic hyperplasia (BPH) and male pattern baldness (MPB), was found to be associated with a lower risk of prostate cancer by inhibition of the conversion of testosterone to the more potent androgen dihydrotestosterone within the prostate.[23] Respondents who self-reported regular use of finasteride had a lower prevalence of prostate cancer in our study.

A number of limitations should be noted when interpreting these results. Similar to all survey data, recall bias could not be eliminated in our study. Moreover, this is a cross-sectional study. The temporal ambiguity and protopathic bias, which refers to bias from reverse causation, can still exist in our study. Due to the cross-sectional nature of our study, only the association, but not the causality, between the variables can be drawn from the findings. The prevalence of prostate cancer in our study was based on respondent self-report. Respondents reported whether they were told by a doctor or a health professional that they were diagnosed with prostate cancer. However, no confirmation of this diagnosis was made. The diagnosis made by only 1 health professional without external confirmation can raise potential inaccuracy in the diagnosis. Although NHIS is a valid and reliable survey,[66,67] the inaccuracy of diagnosis due to the questionnaire design could still threaten the validity of our study. Further, for some questions, we cannot determine the rationale for respondents’ self-reported answers. For example, we were not able to determine if a respondent having multiple PSA tests in the past 5 years was for preventive purposes or a consequence of prostate cancer. Because we used existing survey data, we did not have ideal information on medications, such as statins,[68,69] metformin,[65,68,70] or dutasteride,[71] which may potentially be associated with a reduced risk of prostate cancer. Unmeasured confounding related to these medications may exist. However, we adjusted for finasteride use, which has a similar anticanerogenic effect in prostate cancer cells as dutasteride.[22,23] Thus, the confounding effect from dutasteride would be minimal. Finally, we could not obtain medication use information regarding dosage and duration of aspirin use.

Our study provides a first step to evaluate the association between regular aspirin use and a lower self-reported prevalence of prostate cancer in the United States. A longitudinal study with a longer follow-up period, and also detailed dosage and intake duration information, is necessary. To further investigate the association between regular aspirin use and prostate cancer, future research could be conducted by using a randomized controlled study design, or more efficiently by using longitudinal administrative claims data.

5. Conclusions

Our study was based on a nationally representative sample of rich survey data. The results indicated that regular aspirin use was found to be significantly associated with a lower self-reported prevalence of prostate cancer in the US male population in 2010. Further clinical trials and cohort studies with a longer study period are merited to investigate the mechanism and confirm the causality between regular aspirin use and prostate cancer risk.
References

[1] Curado MP, Edwards B, Shin HR, Storm H, et al. GLOBOCAN 2012: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available at: http://globocan.iarc.fr/Default.aspx. January 2015.

[2] Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195–200.

[3] Haas GP, Delongchamps N, Brawley OW, et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008;15:3866–71.

[4] Taborrof KR, Lund J, Kepka D, et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prevent 2011;20:2006–14.

[5] Rahib L, Smith BD, Azizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–21.

[6] Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews Cancer 2001;1:111–21.

[7] Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883–90.

[8] Luo T, Yan HM, He P, et al. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2012;131:581–7.

[9] Cui Y, Deming-Halverson SL, Shrubsole MJ, et al. Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treatment 2014;146:439–46.

[10] Xu J, Yin Z, Gao W, et al. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin Lung Cancer 2012;13:544–51.

[11] Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2006;12:3006–11.

[12] Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73–8.

[13] Kirschbaum A, Liu X, Yao S, et al. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:suppl 1:127–31.

[14] Madaan S, Howard LE, Moreira DM, et al. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 2015;21:756–62.

[15] Mandair D, Rossi RE, Pericleous M, et al. Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr Metab 2014;11:30. http://download.springer.com/static/pdf/702/art%251A10.1186%252F2574%257F07%2535-10.pdf?origin=htmp%3A%2F%2F

[16] Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2003;95:797–80.

[17] Vidal AH, Howland LE, Moreira DM, et al. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 2015;21:756–62.

[18] Cerhan JR, Parker AS, Putnam SD, et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prevent 1999;8:53–60.

[19] Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:6 suppl 1:3–12.

[20] Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of Salpharredact inhibitors for prostate-cancer prevention. N Engl J Med 2011;365:97–9.

[21] Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.

[22] National Center for Health Statistics, Data File Documentation, National Health Interview Survey, 2010. Available at: http://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2010/. Accessed November 2014.

[23] Davidoff AJ. Identifying children with special health care needs in the National Health Interview Survey: a new resource for policy analysis. Health Serv Res 2004;39:53–72.

[24] National Center for Health Statistics. National Health Interview Survey (NHIS): Person Public Use File. 2010. Available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS2010/personyx_freq.pdf (accessed January, 2015).

[25] National Center for Health Statistics. National Health Interview Survey (NHIS): Family Public Use File. 2010. Available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS2010/familyyx_freq.pdf (accessed January, 2015).

[26] Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973;51:95–124.

[27] Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36:1–6.

[28] Andersen RM. National health surveys and the behavioral model of health services use. Med Care 2008;46:647–53.

[29] Jossey-Bass, Kominski GF. Changing the U.S. health care system: key issues in health services policy and management. In: Kominski GF, Andersen RM, Improving Access to Care. 4th ed. San Francisco, CA, 2013.

[30] Wang X, Liu YW, Wu J, et al. Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg Oncol 2014;12:304. http://download.springer.com/static/pdf/702/art%251A10.1186%252F2574%257F07%2535-10.pdf?origin=htmp%3A%2F%2F

[31] National Center for Health Statistics, Data File Documentation, National Health Interview Survey: a new resource for policy analysis. In: Kominski GF, Andersen RM, Improving Access to Care. 4th ed. San Francisco, CA, 2013.

[32] Carter BD, Abnet CC, Feskanchik D, et al. Smoking and mortality: beyond established causes. N Engl J Med 2015;372:631–40.

[33] Sawada N, Inoue M, Iwasaki M, et al. Alcohol and smoking and subsequent risk of prostate cancer in Japanese men: the Japan Public Health Center-based prospective study. Int J Cancer 2014;134:971–8.

[34] Park SY, Haiman CA, Cheng I, et al. Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes Control 2013;24:1057–15.

[35] Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732–40.

[36] Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer 2015;112:580–93.

[37] Antonelli JA, Jones LW, Banez LL, et al. Exercise and prostate cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer 2015;112:109–37.

[38] Sawada N, Inoue M, Iwasaki M, et al. Alcohol and smoking and subsequent risk of prostate cancer in Japanese men: the Japan Public Health Center-based prospective study. Int J Cancer 2014;134:971–8.

[39] Park SY, Haiman CA, Cheng I, et al. Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the Multiethnic Cohort Study. Cancer Causes Control 2013;24:1057–15.

[40] Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732–40.

[41] Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer 2015;112:580–93.

[42] Antonelli JA, Jones LW, Banez LL, et al. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol 2009;182:2226–31.

[43] Oliveira SA, Lee IM. Is exercise beneficial in the prevention of prostate cancer? Sports Med 1997;23:271–8.

[44] Roether RG, Pal N, Tennant C, et al. Effects of health insurance and lifestyle factors on the risk of prostate cancer in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732–40.

[45] Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer 2015;112:580–93.

[46] Antonelli JA, Jones LW, Banez LL, et al. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol 2009;182:2226–31.

[47] Oliveira SA, Lee IM. Is exercise beneficial in the prevention of prostate cancer? Sports Med 1997;23:271–8.

[48] Roether RG, Pal N, Tennant C, et al. Effects of health insurance and lifestyle factors on the risk of prostate cancer in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732–40.
[50] Park SW, Kim JY, Kim YS, et al. A milk protein, casein, as a proliferation promoting factor in prostate cancer cells. World J Men Health 2014;32:76–82.
[51] Qin LQ, Xu JY, Wang PY, et al. Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. Asia Pac J Clin Nutr 2007;16:467–76.
[52] Datta M, Schwartz GG. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 2012;17:1171–9.
[53] Schenk JM, Till CA, Tangen CM, et al. Serum 25-hydroxyvitamin d concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prevent 2014;23:1484–93.
[54] Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981–90.
[55] Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548–92.
[56] Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385–9.
[57] Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Institute 2003;95:1240–4.
[58] Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674–85.
[59] Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer epidemiol Biomarkers Prevent 2006;15:2056–62.
[60] Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocrine Relat Cancer 2009;16:1103–23.
[61] SAS Institute Inc. [computer program]. Version 9.4: SAS Institute Inc., Cary, NC, USA; 2013.
[62] Andrews J, Dijkstra D, Kryger S, et al. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 2002;50:277–84.
[63] Mahmud SM, Franco EL, Turner D, et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PloS One 2011;6:e16412.
[64] Brasky TM, Velicer CM, Kristal AR, et al. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VIIAnts And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prevent 2010;19:3185–8.
[65] Finney Rutten LJ, Messner HI, Breen N, et al. Factors associated with men’s use of prostate-specific antigen screening: evidence from Health Information National Trends Survey. Prevent Med 2005;40:461–8.
[66] Hamilton JG, Breen N, Klubunde CN, et al. Opportunities and challenges for the use of large-scale surveys in public health research: a comparison of the assessment of cancer screening behaviors. Cancer Epidemiol Biomarkers Prevent 2015;24:3–14.
[67] Parsons VL, Moriarity C, Jonas K, et al. Design and estimation for the national health interview survey, 2006–2015. Vital and Health Statistics Series 2 2006-2015;2014:1–33.
[68] Pon D, Abe A, Gupta EK. A review of statin use and prostate cancer. Curr Atheroscler Rep 2015;17:474. http://download.springer.com/static/pdf/260/art%253A10.1007%252Fs11883-014-0474-5.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs11883-014-0474-5&token2=exp=1465887698∼acl=%2Fstatic%2Fpdf%2F260%2Fart%253A10.1007%252Fs11883-014-0474-5.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs11883-014-0474-5.%3Fhmac=eafa60fc7851790ce65dce50a7e124c3002a490cfa9313d4040537afa6
[69] Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol Biomarkers Prevent 2007;16:2218–25.
[70] Tseng CH. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer (Oxford, England: 1990) 2010;46:2831–7.
[71] Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192–202.